Vial-up: Althea adds fill/finish capabilities in California

By Staff Reporter

- Last updated on GMT

I*mage: iStock/Neznam
I*mage: iStock/Neznam

Related tags: Pharmacology, Active ingredient, Pharmaceutical drug

A vial filling line at Ajinomoto Althea’s manufacturing site in San Diego will maximise yield and reduce product loss, the CMO says.

The Optima VFVM 7000 aseptic fill finish line will be installed in the contract manufacturing organisation’s (CMO) Building 3 facility at its site in San Diego, California and will be operational in Q2 2018, spokeswoman Kristi Gines told this publication.

The installation will be used for customers’ biologic, vaccine, and small molecule fill/finish projects, and comes as a response to concerns regarding the costs of active pharmaceutical ingredients (APIs).

“A key driver for this project was the ability to maximize yield from the filling line as all of our clients are concerned with the cost of manufacturing API,”​ she said.

She added the new line will offer a number of features and benefits to its clients:

“This line has the capability to use two different pumping systems, rotary piston and peristaltic. The ability to use single use disposable filling assemblies in conjunction with peristaltic pumps is a key feature,”​ she said.

The line will also have a wide range of vial sizes, from 2mL up to 100mL, and will include nitrogen flushing and an increased batch size.

“This line has features to minimize drug product loss including start and end of production modes, specialised filling mode for larger volume products – 20 mL to 100 mL – and 100% in process control.”

The expansion is the latest for the company, formed in 2013 when Tokyo-based chemical company Ajinomoto bought US CMO Althea for $175m, including its biopharmaceutical production capabilities for microbial-derived recombinant proteins and plasmid DNA, upstream and downstream process development, analytical development, lyophilisation cycle, complex formulation, product release, ICH stability testing and cGMP vial and syringe filling.

A  57,000 sq ft facility​ offering outsourced ADC (antibody drug conjugate) and HPAPI (highly potent active pharmaceutical ingredient) manufacturing recently opened at the San Diego site.

Related news

Related products

show more

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

The battle of performance in pharma production

The battle of performance in pharma production

Telstar Life Science Solutions | 26-Mar-2019 | Case Study

Telstar case study. Discover how a versatile freeze-dryer automatic loading & unloading systemDiscover how a versatile freeze-dryer automatic loading...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 17-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Related suppliers